Latest Articles
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - MSN
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer MSN
Published: June 16, 2025, 11:46 a.m.
Corrigendum: Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity - Frontiers
Corrigendum: Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity Frontiers
Published: June 16, 2025, 9:30 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Insider Monkey
Published: June 15, 2025, 9:42 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Yahoo
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Yahoo
Published: June 15, 2025, 9:39 a.m.
Multi-Omics Analysis of the Anti-Cancer Effects of Curcumol in Endometrial Carcinoma - Frontiers
Multi-Omics Analysis of the Anti-Cancer Effects of Curcumol in Endometrial Carcinoma Frontiers
Published: June 13, 2025, 5:14 a.m.
S2 Episode 6: Sequencing Antibody-Drug Conjugates in Endometrial Cancer - Medscape
S2 Episode 6: Sequencing Antibody-Drug Conjugates in Endometrial Cancer Medscape
Published: June 12, 2025, 1:50 p.m.
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Yahoo
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer Yahoo
Published: June 10, 2025, 9:47 a.m.
T3-THR Signaling Governed by DIO2 Contributes to Endometrial Receptivity by Regulating Epithelial Cell Membrane Fluidity - Endocrine Society
T3-THR Signaling Governed by DIO2 Contributes to Endometrial Receptivity by Regulating Epithelial Cell Membrane Fluidity Endocrine Society
Published: June 10, 2025, 9:27 a.m.
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Clinical Trials Arena
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer Clinical Trials Arena
Published: June 10, 2025, 9:06 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly
Published: June 10, 2025, 6:31 a.m.
Link copied to clipboard!